Bayforest Capital Ltd Acquires 2,503 Shares of DaVita Inc. $DVA

Bayforest Capital Ltd grew its holdings in DaVita Inc. (NYSE:DVA) by 331.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,259 shares of the company’s stock after buying an additional 2,503 shares during the quarter. Bayforest Capital Ltd’s holdings in DaVita were worth $499,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Ameriprise Financial Inc. raised its stake in shares of DaVita by 27.2% in the fourth quarter. Ameriprise Financial Inc. now owns 32,545 shares of the company’s stock worth $4,867,000 after acquiring an additional 6,951 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of DaVita during the fourth quarter valued at $322,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of DaVita during the 4th quarter worth approximately $106,000. Deutsche Bank AG boosted its stake in DaVita by 35.2% in the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company’s stock valued at $58,687,000 after acquiring an additional 102,230 shares during the last quarter. Finally, Ethic Inc. grew its holdings in DaVita by 116.7% during the 4th quarter. Ethic Inc. now owns 4,345 shares of the company’s stock worth $650,000 after acquiring an additional 2,340 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the subject of several analyst reports. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Friday, August 22nd. Barclays lowered their price objective on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Truist Financial set a $148.00 target price on DaVita in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $164.00.

Insider Activity

In other DaVita news, insider James O. Hearty sold 2,351 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company’s stock.

DaVita Trading Up 1.7%

NYSE DVA opened at $136.73 on Wednesday. The stock has a market capitalization of $9.78 billion, a price-to-earnings ratio of 13.44, a PEG ratio of 0.96 and a beta of 1.13. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The stock’s 50 day moving average price is $139.04 and its two-hundred day moving average price is $141.73. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.